surpass 5 tirzepatide Efficacy and safety of in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase 3 trial Results of SURPASS-1-5 for tirzepatide

As optometrists, we must be mindful of any potential adverse effects our patients medications might have on their overall health and/or on their existing health conditions

The FTO gene variant (rs9939609) influences not just hunger but also circadian rhythm sensitivity, meaning some patients benefit more dramatically from GLP-1's sleep-regulating effects while others experience a gentler transition

Another study of 125,474 people with obesity or who are overweight found that almost 47% of those with Type 2 diabetes and nearly 65% of those without diabetes stopped taking GLP-1s within a year a high rate, said Ezekiel Emanuel, a health services researcher at the University of Pennsylvania and senior author of the study

Before considering this combination, your provider should assess your baseline oxidative stress status, medication interactions, kidney and liver function, and whether evidence supports intervention